# US 2019/0314374 A1 · Calmodulin inhibitors, chk2 inhibitors and rsk inhibitors for the treatment of ribosomal disorders and ribosomapathies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314374 A1
- Document ID: US20190314374A1
- Status: Published application
- Kind: A1
- Application number: 16/315,899
- Filed: 2017-07-13
- Published: 2019-10-17
- Earliest claimed: 2016-07-13
- Assignees: Children's Medical Center Corporation; Dana-Faber Cancer Institute, Inc.
- Applicants: The Children's Medical Center Corporation; Dana-Farber Cancer Institute, Inc.
- Inventors: James BRADNER; Jun QI; Dennis BUCKLEY; Leonard I. ZON; Elizabeth MACARI
- Web page: https://patentgrep.com/patent/US20190314374A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/225: Polycarboxylic acids
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 7/06: Antianaemics
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.

## Claims

### Claim 1

A method of treating a subject with a ribosomal disorder or ribosomopathy, comprising:
(i) administering an effective amount of a composition comprising an inhibitor of ribosomal s6 kinase, RSK (p90S6k), to the subject to decrease p90S6K activity and decrease active p53 in at least one of CD34+ cells, erythroid cells or erythroid differentiated cells in the subject;
(ii) administering an effective amount of a composition comprising an inhibitor of RSK (p70S6K) to the subject to decrease p70S6K activity and decrease active p53 in at least one of CD34+ cells, erythroid cells or erythroid differentiated cells in the subject;
(iii) administering an effective amount of a composition comprising an inhibitor of Chk2 to the subject to decrease active p53 in at least one of CD34+ cells, erythroid cells or erythroid differentiated cells in the subject, wherein the inhibitor of Chk2 comprises a compound selected from the group consisting of CCT and III, or derivatives thereof, wherein CCT and III have the following structures:
(iv) administering an effective amount of a composition comprising an inhibitor of calmodulin to the subject to decrease active p53 in at least one of CD34+ cells, erythroid cells or erythroid differentiated cells in the subject, wherein the inhibitor of calmodulin is a phenothiazine compound, or a derivative or analogue of the phenothiazine compound, wherein the phenothiazine compound is selected from the group consisting of ACV-1-235 (ACV), JJM-II-221E (221E) and DB1026(PerSucc), wherein ACV-1-235 (ACV), JJM-II-221E (221E) and DB1026(PerSucc) have the following structures:
(v) administering an effective amount of a composition comprising a phenothiazine compound, or a derivative or analogue of the phenothiazine compound, wherein the phenothiazine compound is selected from the group consisting of DB-4-083 (083), DB-4-084 (084), DB-4-088-2 (088-2), DB-4-088-3 (088-3), DB-4-086 (086), DB-4-087-2 (087-2), DB-4-087-3 (087-3) and DB-4-089 (089), wherein DB-4-083 (083), DB-4-084 (084), DB-4-088-2 (088-2), DB-4-088-3 (088-3), DB-4-086 (086), DB-4-087-2 (087-2), DB-4-087-3 (087-3) and DB-4-089 (089) have the following structures
(vi) administering an effective amount of a composition comprising a phenothiazine compound, or a derivative or analogue of the phenothiazine compound, wherein the phenothiazine compound is a compound of Formula (I):
wherein:
X is O or S;
R1 is H, alkyl, alkenyl, alkynyl, cyclyl, heterocyclyls, acyl, aryl, heteroaryl, alkylheteroaryl or alkylaryl;
each R is independently H, halo, alkyl, alkyl, alkenyl, alkynyl, haloalkyl, CN, OH, NH2, alkylamino, dialkylamino, CO2H, acyl, SH, thioalkoxy, SOH, or SO3H; and isomers and pharmaceutically acceptable salts thereof;
(v) administering an effective amount of a composition comprising a a phenothiazine compound, or a derivative or analogue of the phenothiazine compound, wherein the phenothiazine compound is a compound of Formula (II):
wherein:
each R21 is independently selected from the group consisting of H, halo, alkyl, haloalkyl, CN, OH, NH2, alkylamino, dialkylamino, CO2H, acyl, SH, thioalkoxy, SO2H, and SO3H; isomers and pharmaceutically acceptable salts thereof;
(vi) administering an effective amount a composition comprising a phenothiazine compound, or a derivative or analogue of the phenothiazine compound, wherein the phenothiazine compound is a compound of structure:
or
(vii) administering an effective amount of the is a calcium channel blocker BAPTA-AM or derivative or analogue thereof to the subject to decrease active p53 in at least one of CD34+ cells, wherein BAPTA-AM has the following structure:

### Claim 2 (depends on 1)

The method of claim 1, wherein the inhibitor of p90S6k inhibits a variant selected from the group consisting of RSK1, RSK2 and RSK3.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inhibitor of p90S6k selectively inhibits RSK2.

### Claim 4 (depends on 1)

The method of claim 1, wherein the inhibitor of p90S6k or p70S6k is a nucleic acid, a small molecule compound, or a protein.

### Claim 5 (depends on 1)

The method of claim 1, wherein:
(i) the inhibitor of p90S6k is SL0101 (SL), or a derivative or analogue of SL0101 (SL), wherein SL0101 (SL) has the following structure:
or
(ii) the inhibitor of p90S6k is BI-D1870 (BI) or a derivative or analogue of BI-D1870 (BI), wherein BI-D1870 (BI) has the following structure:

### Claim at position 6

-8. (canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the inhibitor of p70S6k is PF-4708671 (PF), or a derivative or analogue of PF-4708671 (PF), wherein PF-4708671 (PF) has the following structure:

### Claim at position 8

-16. (canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein the subject with a ribosomal disorder has Diamond Blackfan Anemia (DBA) or inherited erythroblastopenia.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein the subject has a mutation in ribosomal protein 19 (RPS19).

### Claim at position 12

-21. (canceled)

### Claim 22 (depends on 1)

The method of claim 1, wherein the subject is administered another therapeutic agent to treat the ribosomal protein defect, selected from the group consisting of: corticosteroids, blood transfusions.

### Claim at position 14

-25. (canceled)

### Claim 26 (depends on 1)

The method of claim 1, wherein the subject has a symptom of macrocytic anemia or craniofacial abnormalities.

### Claim 27 (depends on 1)

The method of claim 1, wherein the ribosomopathy is myelodysplasia.

### Claim 28 (depends on 1)

The method of claim 1, wherein the myelodysplasia is 5q-myelodysplasia.

### Claim 29 (depends on 1)

The method of claim 1, wherein subject has a symptom of dysplastic bone marrow.

### Claim 30 (depends on 1)

The method of claim 1, wherein the ribosomopathy is Shwachman-Diamond syndrome.

### Claim 31 (depends on 1)

The method of claim 1, wherein the subject has a mutation in Sbds.

### Claim 32 (depends on 1)

The method of claim 1, wherein subject has a symptom selected from: pancreatic insufficiency, bone marrow dysfunction, skeletal deformities.

### Claim 33 (depends on 1)

The method of claim 1, wherein the ribosomopathy is Treacher Collins Syndrome.

### Claim 34 (depends on 1)

The method of claim 1, wherein the subject has a mutation in TCOF1 (nucleolar).

### Claim 35 (depends on 1)

The method of claim 1, wherein the subject has a symptom of craniofacial deformities.
